ABOUT US PRICING DOCS SIGN IN ABOUT US The story The founders Advisory board The story We established mcule.com in 2011 with the aim to create the best drug discovery platform available online. In 2008, two of the founders of mcule.com published one of the largest virtual screen in a drug discovery project. They were able to screen millions of compounds and found novel active molecules for treating asthma and allergy. The high level of integration between drug discovery tools and computational power was the key to success. The four founders (Robert, Ferenc, Mark and Zoltan) realized that with an integrated drug discovery platform researchers could achieve things that were impossible in the past. In that moment, the idea of mcule.com was born. Even though the pharma industry spends billions of dollars on research, only 1 out of 10 new projects is successful in the clinical trials. The success depends on the quality of the drug candidates. Experts agree that the quality of the drug candidates is mainly depending on the quality of the initial hits. Thus the success of drug discovery depends on finding the best drug candidates in the haystack of the chemical space as early as possible. Mcule helps scientists at biotech and pharma companies to find new drug candidates quickly and efficiently so they can start working on the new blockbuster they have always longed for. Mcule offers an integrated drug discovery platform with the following components: 1. Compound Sourcing search, find and order compounds from the highest quality database of purchasable compounds with only a few clicks 2. Hit identification your simplest solution for molecular modelling: no computers, no installation, no programming skills, not expensive but highest quality modelling tools We envisage a future where researchers can use mcule.com as a daily tool for all their preclinical studies. The Founders Ferenc Szalai, CEO is a physicist who has worked for CERN LHC and a numerous international high-performance, grid and cloud computing projects. Author of several scientific publication on the field. He designed, operated and developed large-scale computing systems and web services. He is an active member of the Hungarian start-up community with management experience. Róbert Kiss, Ph.D., CSO has a PhD in pharmacy and has worked for Gedeon Richter Plc. He is member of the American Chemical Society and has numerous scientific publications including journal papers and book chapters. He has 10 years of experience in the field of drug discovery focusing on molecular modeling and virtual screening. Márk Sándor, Chief Cheminformatician is a physicist who has worked for Gedeon Richter Plc. He has gained experience in the field of molecular modeling, cheminformatics, and design of molecule databases. Zoltán Szalai, CTO, lead developer is an IT specialist, who has been working as a frontend / backend lead developer in web- and desktop projects in the past 8 years. He has relevant experience regarding modern web technologies and user experience design. Advisory board Peter Cohan Peter Cohan has an MS in Chemistry. He is the founder and principal of The Second Derivative improving sales and marketing results. Founded the discovery Tools business unit at Symyx Technologies, growing the business from 0 to $30M. Board member of Collaborative Drug Discovery, Inc. Sunil Maulik Sunil Maulik has a Ph.D. in BioPhysics. He is VP Business Development at Designit, Silicon Valley. Helped take the first drug design company to IPO. Former Head of Bioinformatics at Roche. Founded and lead life science company to profitability and is experienced in raising funds. György Miklós Keserű György is Director general at the Research Centre for Natural Sciences, Hungarian Academy of Sciences. Before this position he was the Head of Discovery Chemistry at Gedeon Richter Plc, where he was responsible for all discovery chemistry activities including classic and automated medicinal chemistry, computer assisted drug discovery (CADD), compound management and high throughput screening (HTS). He is a member of several chemical and modelling societies, editorial board member of scientific journals and the author of more than 100 publications. György is giving invaluable advises on the development strategy of mcule's modeling platform. Free account Create a free account to start using mcule.com and get unlimited access to simple searching tools and limited access to more powerful tools. CREATE A FREE ACCOUNT About mcule.com Mcule.com is an online drug discovery platform. It offers a unique solution for pharma and biotech companies by providing molecular modeling tools and the highest quality purchasable compound database. Mcule, Inc. 535 Everett Ave #410 Palo Alto, CA 94301 USA info@mcule.com EIN: 46-2751332 mcule.com Kft. Fehervari ut 130. H-1116, Budapest Hungary info@mcule.com VAT Number: HU23383540 Blog About Us Pricing Docs Contact Partners Research Accelerator Program Sign in Sign up Privacy Terms of service © 2015 mcule.com